BIOGRAPHY: Dr. Jean Bourbeau is a clinician scientist, professor, and full-time researcher at McGill University who is trained as a Respirologist in epidemiology and biostatistics from McGill University, and Senior Scientist at the Center of Outcome Research and Evaluation (CORE), Research Institute McGill University Health Centre (RIMUHC). He is a Fellow of the Canadian Academia of Health Science (FCAHS), has received the “Distinguished Scientist Award”, McGill University (2020-2025), “CIHR- ICRH/CTS Distinguished Lecturer Award in Respiratory Sciences (2024)”.

Dr. Bourbeau is recognized as a leading researcher around the globe and leader in COPD with over 400 publications. He currently serves on various international/national COPD scientific committees (Global Initiative for Chronic Obstructive Lung Disease (GOLD), Chest, ATS and CTS). Past President and currently on the board of the CTS. Research, mainly clinical and epidemiological in the field of COPD, including the Canadian Cohort Obstructive Lung Disease (CanCOLD), and the self-management program Living Well with COPD (LWWCOPD), that have had impact in clinical practice and patient education.

He has been the principal investigator of many clinical trials and his past achievements include:

• landmark multicentre RCTs of COPD non-pharmacological interventions (Self- management/FRQS, home rehabilitation/CIHR, COMET, PHYSACTO industry funded/investigator initiated)
• Current achievement: drug (fentanyl S/L) and device (OPEP) RCTs (cross over design) for refractory dyspnea in COPD (CIHR funding), and home rehab-lung COVID RCT (CIHR finding).
• Nominated principal investigator, CIHR Clinical Training Trial Platform, the CANadian consortium of the clinical trial TRAINing platform (CANTRAIN), 11.3 M$ (2022-2025).
• Co-chair of the training committee, and chair of the new Clinical Trial Network “Chronic Airway Disease Clinical Trial Network” as part of the Accelerating Controlled Trials (ACT) Consortium CIHR (2022-26).